

Tumor control versus adverse events with targeted ant

Nature Reviews Clinical Oncology

9, 98-109

DOI: [10.1038/nrclinonc.2011.192](https://doi.org/10.1038/nrclinonc.2011.192)

Citation Report

#	ARTICLE	IF	CITATIONS
1	New Frontiers in Mucositis. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 545-551.	3.8	21
2	Protein pathway activation mapping reveals molecular networks associated with antiestrogen resistance in breast cancer cell lines. International Journal of Cancer, 2012, 131, 1998-2007.	5.1	25
3	Safe and targeted anticancer therapy for ovarian cancer using a novel class of curcumin analogs. Journal of Ovarian Research, 2013, 6, 35.	3.0	20
4	Emerging evidence on the pathobiology of mucositis. Supportive Care in Cancer, 2013, 21, 3233-3241.	2.2	145
5	Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysis. Supportive Care in Cancer, 2013, 21, 3243-3254.	2.2	46
6	Identification of dasatinib as an in vitro potent growth inhibitor of canine histiocytic sarcoma cells. Veterinary Journal, 2013, 196, 536-540.	1.7	9
7	In vivo uptake and cellular distribution of gold nanoshells in a preclinical model of xenografted human renal cancer. Gold Bulletin, 2013, 46, 257-265.	2.4	19
8	A self-assembled nanocarrier loading teniposide improves the oral delivery and drug concentration in tumor. Journal of Controlled Release, 2013, 166, 30-37.	9.9	47
9	The proteasome inhibitor bortezomib inhibits the growth of canine malignant melanoma cells in vitro and in vivo. Veterinary Journal, 2013, 198, 577-582.	1.7	14
10	Targeting Near the End of Life in Patients With Cancer. Journal of Pain and Symptom Management, 2013, 45, e3-e4.	1.2	3
11	Mucositis. , 2013, , 121-146.		0
12	Emerging evidence on the pathobiology of mucositis. Supportive Care in Cancer, 2013, 21, 2075-2083.	2.2	121
13	Paradoxical oncogenesis—the long-term effects of BRAF inhibition in melanoma. Nature Reviews Clinical Oncology, 2013, 10, 390-399.	27.6	171
14	Pathobiology of Cancer Regimen-Related Toxicities. , 2013, , .		5
15	Replica to K. Takeda et al. Commentary to Pastore et al. (2014): Epidermal growth factor receptor signalling in keratinocyte biology: implications for skin toxicity of tyrosine kinase inhibitors. Archives of Toxicology, 2014, 88, 2321-2322.	4.2	3
16	TOPK inhibitor induces complete tumor regression in xenograft models of human cancer through inhibition of cytokinesis. Science Translational Medicine, 2014, 6, 259ra145.	12.4	95
17	Accessibilome of Human Glioblastoma: Collagen-VI-alpha-1 Is a New Target and a Marker of Poor Outcome. Journal of Proteome Research, 2014, 13, 5660-5669.	3.7	26
18	Overcoming barriers to the implementation of patient-reported outcomes in cancer clinical trials: the PROMOTION Registry. Health and Quality of Life Outcomes, 2014, 12, 86.	2.4	31

#	ARTICLE	IF	CITATIONS
19	Mass Spectrometry-Based Serum and Plasma Peptidome Profiling for Prediction of Treatment Outcome in Patients With Solid Malignancies. <i>Oncologist</i> , 2014, 19, 1028-1039.	3.7	21
20	Multifunctional pentacyclic triterpenoids as adjuvants in cancer chemotherapy: a review. <i>RSC Advances</i> , 2014, 4, 33370-33382.	3.6	44
21	Epidermal growth factor receptor signalling in keratinocyte biology: implications for skin toxicity of tyrosine kinase inhibitors. <i>Archives of Toxicology</i> , 2014, 88, 1189-1203.	4.2	47
22	The changing paradigm for supportive care in cancer patients. <i>Supportive Care in Cancer</i> , 2014, 22, 1441-1445.	2.2	13
23	Automatic signal extraction, prioritizing and filtering approaches in detecting post-marketing cardiovascular events associated with targeted cancer drugs from the FDA Adverse Event Reporting System (FAERS). <i>Journal of Biomedical Informatics</i> , 2014, 47, 171-177.	4.3	33
24	Proteolytic cleavage, trafficking, and functions of nuclear receptor tyrosine kinases. <i>FEBS Journal</i> , 2015, 282, 3693-3721.	4.7	73
25	Targeting Breast Cancer Metastasis. <i>Breast Cancer: Basic and Clinical Research</i> , 2015, 9s1, BCBCR.S25460.	1.1	145
26	TACC3 promotes stemness and is a potential therapeutic target in hepatocellular carcinoma. <i>Oncotarget</i> , 2015, 6, 24163-24177.	1.8	54
27	A spectrum of cutaneous toxicities from erlotinib may be a robust clinical marker for non-small-cell lung therapy: a case report and literature review. <i>OncoTargets and Therapy</i> , 2015, 8, 943.	2.0	5
28	Oral Mucositis Induced By Anticancer Therapies. <i>Current Oral Health Reports</i> , 2015, 2, 202-211.	1.6	134
29	Avasimibe Encapsulated in Human Serum Albumin Blocks Cholesterol Esterification for Selective Cancer Treatment. <i>ACS Nano</i> , 2015, 9, 2420-2432.	14.6	68
30	Large-scale automatic extraction of side effects associated with targeted anticancer drugs from full-text oncological articles. <i>Journal of Biomedical Informatics</i> , 2015, 55, 64-72.	4.3	20
31	Evaluation of different phospho-tyrosine antibodies for label-free phosphoproteomics. <i>Journal of Proteomics</i> , 2015, 127, 259-263.	2.4	43
32	Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments. <i>Annals of Oncology</i> , 2015, 26, 2034-2043.	1.2	241
33	ErbB small molecule tyrosine kinase inhibitor (TKI) induced diarrhoea: Chloride secretion as a mechanistic hypothesis. <i>Cancer Treatment Reviews</i> , 2015, 41, 646-652.	7.7	53
34	Pharmacogenomic biomarkers for personalized cancer treatment. <i>Journal of Internal Medicine</i> , 2015, 277, 201-217.	6.0	57
35	Gastrointestinal toxicities of first and second-generation small molecule human epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. <i>Current Opinion in Supportive and Palliative Care</i> , 2016, 10, 152-156.	1.3	6
36	Evaluation of a tyrosine kinase peptide microarray for tyrosine kinase inhibitor therapy selection in cancer. <i>Experimental and Molecular Medicine</i> , 2016, 48, e279-e279.	7.7	22

#	ARTICLE	IF	CITATIONS
37	Molecular Targets in Advanced Therapeutics of Cancers: The Role of Pharmacogenetics. <i>Oncology</i> , 2016, 91, 3-12.	1.9	14
38	Molecular mechanisms for vascular complications of targeted cancer therapies. <i>Clinical Science</i> , 2016, 130, 1763-1779.	4.3	18
39	Doxorubicin-induced co-assembling nanomedicines with temperature-sensitive acidic polymer and their in-situ -forming hydrogels for intratumoral administration. <i>Journal of Controlled Release</i> , 2016, 235, 328-336.	9.9	41
40	Synthesis and Evaluation of ¹³¹ I-Skyrin as a Necrosis Avid Agent for Potential Targeted Radionuclide Therapy of Solid Tumors. <i>Molecular Pharmaceutics</i> , 2016, 13, 180-189.	4.6	11
41	Systematic Review of the Side Effects Associated With Anti-HER2-Targeted Therapies Used in the Treatment of Breast Cancer, on Behalf of the EORTC Quality of Life Group. <i>Targeted Oncology</i> , 2016, 11, 277-292.	3.6	27
42	Dacomitinib-induced diarrhoea is associated with altered gastrointestinal permeability and disruption in ileal histology in rats. <i>International Journal of Cancer</i> , 2017, 140, 2820-2829.	5.1	27
43	Cutaneous Side Effects and Transepidermal Water Loss To Gefitinib: A Study of 11 Patients. <i>Dermatology and Therapy</i> , 2017, 7, 133-141.	3.0	7
44	Polymorphisms in Pharmacogenetics of Personalized Cancer Therapy. , 0, , .		4
45	Kinase Inhibitors. , 2017, , 57-80.		0
48	“No pain, No gain” still true with immunotherapy: When the finger shows the moon, look at the moon!. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 127, 1-5.	4.4	4
49	Oral stomatitis and mTOR inhibitors: A review of current evidence in 20,915 patients. <i>Oral Diseases</i> , 2018, 24, 144-171.	3.0	18
50	The epidermal growth factor receptor inhibitor AG1478 inhibits eosinophilic inflammation in upper airways. <i>Clinical Immunology</i> , 2018, 188, 1-6.	3.2	15
51	Trial watch: Peptide-based vaccines in anticancer therapy. <i>Oncolmmunology</i> , 2018, 7, e1511506.	4.6	121
52	Life-threatening Hyperkalemia Associated with Axitinib Treatment in Patients with Recurrent Renal Carcinoma. <i>Internal Medicine</i> , 2018, 57, 2895-2900.	0.7	7
53	Stomatitis and VEGFR-Tyrosine Kinase Inhibitors (VR-TKIs): A Review of Current Literature in 4369 Patients. <i>BioMed Research International</i> , 2018, 2018, 1-16.	1.9	10
54	Mouth. , 2018, , 1-17.		0
55	Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development. <i>Theranostics</i> , 2018, 8, 894-905.	10.0	72
56	Severe Pain Due to Paraspinal Abscess Formation in Two Patients with Squamous-Cell Carcinoma of the Head and Neck after Multimodal Treatment Including Cetuximab. <i>Oncology Research and Treatment</i> , 2018, 41, 395-398.	1.2	1

#	ARTICLE	IF	CITATIONS
57	Potential Successes and Challenges of Targeted Cancer Therapies. Journal of the National Cancer Institute Monographs, 2019, 2019, .	2.1	26
58	Probabilistic medicine: a pre-emptive approach is needed for cancer therapeutic risk mitigation. Biomarkers in Medicine, 2019, 13, 987-990.	1.4	2
59	Mucositis. , 2019, , 1-17.		0
60	Design, Synthesis and Biological Evaluation of a New Series of 1-Aryl-3-[4-[(pyridin-2-ylmethyl)thio]phenyl]urea Derivatives as Antiproliferative Agents. Molecules, 2019, 24, 2108.	3.8	3
61	Mucositis. , 2019, , 317-333.		0
62	Clinician-reported symptomatic adverse events in cancer trials: are they concordant with patient-reported outcomes?. Journal of Comparative Effectiveness Research, 2019, 8, 279-288.	1.4	4
63	<p>Stomatitis And Everolimus: A Review Of Current Literature On 8,201 Patients</p>. OncoTargets and Therapy, 2019, Volume 12, 9669-9683.	2.0	7
64	Discovery of new fluorescent thiazoleâ€pyrazoline derivatives as autophagy inducers by inhibiting mTOR activity in A549 human lung cancer cells. Cell Death and Disease, 2020, 11, 551.	6.3	19
65	Synthesis and biological evaluation of a new series of 1-aryl-3-[4-(pyridin-2-ylmethoxy)phenyl]urea derivatives as new anticancer agents. Medicinal Chemistry Research, 2020, 29, 1413-1423.	2.4	4
66	In-vitro and in-vivo evaluation of polymeric microsphere formulation for colon targeted delivery of 5-fluorouracil using biocompatible natural gum katira. International Journal of Biological Macromolecules, 2020, 158, 922-936.	7.5	13
67	Antibody-drug combination therapy in cancer treatment. , 2021, , 227-253.		0
68	TLR4 and TLR9 polymorphism: Probable role in susceptibility among the population of Bihar for Indian visceral leishmaniasis. Innate Immunity, 2021, 27, 493-500.	2.4	1
69	State of the art of overcoming efflux transporter mediated multidrug resistance of breast cancer. Translational Cancer Research, 2019, 8, 319-329.	1.0	10
70	Oral Mucositis and Stomatitis Associated with Conventional and Targeted Anticancer Therapy. Journal of Pharmacovigilance, 2013, 01, .	0.2	17
71	Development of â€œon-demandâ€ thermo-responsive hydrogels for anti-cancer drugs sustained release: Rational design, in silico prediction and in vitro validation in colon cancer models. Materials Science and Engineering C, 2021, 131, 112483.	7.3	20
72	Bone Marrow Toxicity: Red Blood Cells. , 2013, , 333-364.		0
73	Ovarian Cancer Relapse: Experimental Therapies. , 2013, , 199-228.		0
74	Bone Marrow Toxicity: Red Blood Cells. , 2018, , 407-426.		0

#	ARTICLE	IF	CITATIONS
75	Adverse effects of targeted cancer treatment. <i>Onkologie (Czech Republic)</i> , 2020, 14, 18-23.	0.1	0
76	tcTKB: an integrated cardiovascular toxicity knowledge base for targeted cancer drugs. <i>AMIA ... Annual Symposium proceedings</i> , 2015, 2015, 1342-51.	0.2	1
77	Antibiotics in prevention of skin toxic reactions of epidermal growth factor receptor inhibitors (literature review). <i>Medical Alphabet</i> , 2021, , 8-11.	0.2	0
78	Compound kushen injection in cancer treatments: Efficacy, active ingredients, and mechanisms. <i>Pharmacological Research Modern Chinese Medicine</i> , 2022, 3, 100108.	1.2	2
79	Docking, Synthesis and Anticancer Activity of 4-(4-(3-(4-Chloro-3-(trifluoromethyl)- Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 587 Td (pheny 2022, 34, 1457-1464.	0.3	2
80	Cross-Resistance Among Sequential Cancer Therapeutics: An Emerging Issue. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	8
81	Supportive and Palliative Care in Cancer Therapiesâ€”Path from Tumor-Driven Therapies to Patient-Driven Ones. <i>International Journal of Clinical Medicine</i> , 2022, 13, 287-359.	0.2	1
82	Personalized Targeted Therapeutic Strategies against Oral Squamous Cell Carcinoma. An Evidence-Based Review of Literature. <i>International Journal of Nanomedicine</i> , 0, Volume 17, 4293-4306.	6.7	10
83	Oncology Clinical Trials in Greece: Progress in the Past Decade. <i>Journal of Long-Term Effects of Medical Implants</i> , 2022, , .	0.7	0
84	Towards UGT1A1 guided irinotecan dosing. <i>European Journal of Human Genetics</i> , 0, , .	2.8	0
85	A novel series of tetrahydrothieno[2,3- <i>c</i></i>]pyridin-2-yl derivatives: fluorescence spectroscopy and BSA binding, ADMET properties, molecular docking, and DFT studies. <i>New Journal of Chemistry</i>, 2023, 47, 11945-11963.</i>	2.8	3
86	Putting a Magnifying Lens on Pharmacogenetics and Pharmacogenomics Associated Challenges and Opportunities in Area of Cancer Research. , 2023, , 1-14.		0
87	Signal Transduction Inhibitors. , 2023, , 89-110.		2
88	Gelatin microsphere-alginate hydrogel combined system for sustained and gastric targeted delivery of 5-fluorouracil. <i>International Journal of Biological Macromolecules</i> , 2024, 255, 128022.	7.5	1
89	A CTLâ€”Inspired Killing System Using Ultralowâ€”Dose Chemicalâ€”Drugs to Induce a Pyroptosisâ€”Mediated Antitumor Immune Function. <i>Advanced Materials</i> , 0, , .	21.0	2
90	Cancer Drug Resistance: Targeting Proliferation or Programmed Cell Death. <i>Cells</i> , 2024, 13, 388.	4.1	0